Advance cardiovascular disease research with high plex protein profiling for biomarker discovery
Target 7,000 proteins from a 55 μl sample to identify novel protein signatures
Discover relevant biomarkers related to cardiac health and disease for prevention, diagnostics, and drug development
Cardiovascular disease (CVD) is the leading cause of mortality worldwide. Identifying novel and early-stage biomarkers is important in predicting and preventing the significant morbidity and mortality associated with CVD. High content analysis of the human plasma proteome is facilitating the possibility for novel biomarker discoveries. This, combined with increasing capacity for analysis of large data sets, opens a world of possibilities for improving cardiovascular care with a more personalized medicine approach.
Look deeper with the SomaScan platform
Multiplex, high-throughput proteomics
Screen up to 7,000 proteins per sample and conduct high-throughput analysis of >1,000 samples simultaneously.
Detect and quantify a wide dynamic range of proteins (from fmol – μmol) in complex sample types such as serum and plasma.
Obtain consistent and reproducible inter- and intraassay results for data analysis and comparison.
Advanced proteomics offerings in CVD
The SomaScan Platform is available in multiple formats, each providing unique data outputs to fast-track your CVD research.
With the ability to profile 7,000 proteins simultaneously and in easily accessible samples such as blood and urine, the SomaScan Assay is well suited to measuring low and highly abundant proteins to identify CVD biomarkers.
These custom panels can be individualized from our menu of 7,000 protein analytes. The assay is also offered as a cardiac panel focused on 953 CVD-relevant proteins, in addition to other curated panels for inflammation and metabolic diseases.
Monitor clinical metrics including those associated with CVD such as body fat percentage, lean body mass, cardiorespiratory fitness, and heart failure-specific tests.
In one of the largest proteomics studies ever conducted, scientists from 18 organizations across the world used the SomaScan Assay to create and validate a 27-protein clinical test model that accurately predicted the 4-year likelihood of myocardial infarction, heart failure, stroke, or death. This model elucidated the underlying biology associated with clinical risk factors and has the potential for consideration as a “universal” surrogate endpoint for CVD risk. (A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk | Science Translational Medicine)
BLOGProteomics and heart failure: improving risk stratification and treatmentProteomics and heart failure: improving risk stratification and treatment. New research suggests that proteomics could improve – or even replace – current techniques for assessing
White paperDetection of low-abundance serum proteins associated with cardiovascular diseases for prognostic purposesAs the leading cause of death in the United States and worldwide, Cardiovascular Disease (CVD) includes a family of diseases that affect the heart and blood vessels. The primary origin of CVD is most often atherosclerotic in nature, in which fatty plaque deposits line arteries and obstruct circulation of blood. The etiology of CVD is multifactorial and is shaped by the interaction of genes and environment and further influenced by age and gender.
WebinarPredicting heart failure using the plasma proteomeTo determine whether the plasma proteome adds value to established predictors in heart failure (HF) with reduced ejection fraction (HFrEF). We sought to derive and validate a plasma proteomic risk score (PRS) for survival in patients with HFrEF (HFrEF-PRS). Until recently, proteomics had not been as thoroughly explored partly due to comparatively low-throughput. However, emerging proteomic technologies have recently matured and newer high-throughput techniques now allow larger scale proteomic characterization. One of these newer technological innovations, enhanced aptamer-based assays, has enabled a massively expanded candidate approach that borders on true proteomics in scale; thousands of protein-derived factors can be efficiently assayed simultaneously in a small biologic sample. In this webinar, you will explore this new large-scale protein array using an established HF patient registry to understand how the plasma proteome could meaningfully predict the risk of death or HF worsening and add to best conventional risk stratification, including clinical score and natriuretic peptides. By using the circulating proteome to improve risk prediction, it could add a new tool to help manage patients with HF and contribute to discovery of novel HF markers and pathways.
See relevant publications in our interactive viewer